CagriSema vs. Tirzepatide (Zepbound): REDEFINE vs. SURMOUNT Data

When Novo Nordisk's Wegovy (semaglutide 2.4 mg) launched in 2021 with 14.9% weight reduction in STEP-1, it set the benchmark for obesity pharmacotherapy. Two years later, Eli Lilly's tirzepatide (Zepbound) shifted the standard upward to 22.5% in SURMOUNT-1 and beat Wegovy by 6.5 percentage points in the direct SURMOUNT-5 head-to-head trial (20.2% vs. 13.7%).

Rather than replicating Lilly's GIP/GLP-1 dual incretin blueprint, Novo Nordisk looked to a distinct endogenous pancreatic hormone: amylin (islet amyloid polypeptide). Co-secreted with insulin from pancreatic beta cells in a 1:100 molar ratio after meals, native amylin signals meal termination (satiation) through the area postrema and nucleus tractus solitarius in the hindbrain, suppresses postprandial glucagon spikes, and regulates gastric emptying. Native human amylin has a half-life of only ~13 minutes and aggregates into amyloid fibrils, which limited the first-generation amylin analog pramlintide (Symlin) to three-times-daily mealtime injections.

Novo Nordisk solved this by engineering cagrilintide (AM833)—a proline-substituted, non-fibrillating 37-amino-acid peptide acylated with a C20 fatty diacid chain that binds serum albumin for a ~160–180 hour (7-day) half-life. Pairing cagrilintide 2.4 mg with semaglutide 2.4 mg created CagriSema.

Although both CagriSema and tirzepatide rely on once-weekly GLP-1 receptor activation as their foundation, their secondary mechanisms act on completely different anatomical circuits:

• CagriSema's DACRA + GLP-1R Dual-Pathway Satiety: Cagrilintide is a Dual Amylin and Calcitonin Receptor Agonist (DACRA). It binds both heteromeric amylin receptors (AMY1R, AMY2R, AMY3R—formed by the calcitonin receptor complexed with receptor activity-modifying proteins RAMP1–3) and homomeric calcitonin receptors (CTR). Crucially, amylin receptors in the area postrema and lateral parabrachial nucleus activate a non-overlapping population of hindbrain neurons distinct from GLP-1R neurons. In preclinical models, combining amylin and GLP-1 agonism produces synergistic (super-additive) suppression of hedonic food intake and restores leptin sensitivity in the ventromedial hypothalamus.
• Tirzepatide's GIPR + GLP-1R Incretin & Adipose Axis: Tirzepatide is a biased agonist at the GLP-1 receptor (favoring cAMP generation over beta-arrestin recruitment, which prevents rapid receptor internalization) while acting as a full agonist at the GIP receptor. Unlike amylin receptors—which are absent from white adipocytes—GIP receptors are densely expressed in subcutaneous white adipose tissue, where they increase adipose blood flow, lipoprotein lipase activity, and insulin-stimulated glucose and triglyceride clearance, preventing ectopic lipid spillover into visceral organs. Simultaneously, GABAergic GIPR neurons in the area postrema inhibit GLP-1-induced emetic circuits.

The Phase 3 clinical readouts for CagriSema provide one of the most nuanced case studies in trial design in modern endocrinology:

REDEFINE-1 (Obesity Without Diabetes, n = 3,417, 68 Weeks): Participants were randomized to CagriSema (2.4 mg / 2.4 mg), cagrilintide 2.4 mg monotherapy, semaglutide 2.4 mg monotherapy, or placebo. On the efficacy estimand (if all participants adhered to treatment), CagriSema produced 22.7% mean weight loss, compared with 11.8% for cagrilintide alone, 16.1% for semaglutide alone, and 2.3% for placebo—proving clear additive synergy between the two peptides. Furthermore, 40.4% of CagriSema patients lost ≥25% of their body weight.

Why Only 57.3% Reached the Maximum Dose in REDEFINE-1: Unlike SURMOUNT-1—which forced randomized cohorts onto fixed maintenance doses of 5 mg, 10 mg, or 15 mg tirzepatide—REDEFINE-1 used a flexible, patient-directed titration protocol that allowed participants to pause dose escalation or step down if they were already losing weight rapidly or experiencing mild GI satiety. Consequently, only 57.3% of participants ever escalated to the top 2.4 mg / 2.4 mg dose by Week 68, yet the overall cohort still averaged 22.7% weight loss (matching SURMOUNT-1's 22.5%).

REDEFINE-2 (Obesity With Type 2 Diabetes, n = 1,206, 68 Weeks): Patients with type 2 diabetes famously lose less weight on incretin therapies than non-diabetic patients due to baseline hyperinsulinemia and glycosuria reduction. In REDEFINE-2, CagriSema achieved 15.7% mean weight loss (efficacy estimand; 13.7% treatment-regimen), slightly edging out tirzepatide's 14.7% (efficacy estimand; 12.8% treatment-regimen) in SURMOUNT-2.

REDEFINE-4 (Direct Head-to-Head vs. Tirzepatide 15 mg, n = 800, 84 Weeks): In the open-label head-to-head trial comparing CagriSema 2.4/2.4 mg directly against tirzepatide 15 mg over 84 weeks, both drugs achieved massive, greater-than-20% weight reductions (~23.0% for CagriSema vs. ~25.5% for tirzepatide 15 mg), demonstrating that while CagriSema closes almost the entire gap between Wegovy and Zepbound, unimolecular tirzepatide 15 mg retains a slight edge at maximum forced titration.

A critical pharmaceutical difference between CagriSema and tirzepatide lies in solution chemistry. Tirzepatide is a single peptide molecule dissolved at neutral pH (~6.5–7.5) in a standard single-chamber pen or vial.

CagriSema contains two separate peptides that cannot be co-formulated in the same liquid buffer for long-term shelf stability: cagrilintide requires a mildly acidic pH (~4.0) to prevent fibrillation and deamidation, whereas semaglutide requires a neutral pH (~7.4) to remain soluble. To administer both in a single once-weekly injection, Novo Nordisk engineered a complex dual-chamber autoinjector pen that stores cagrilintide and semaglutide in two isolated glass cartridges and merges them through a single needle upon injection (while also developing a next-generation unimolecular amylin/GLP-1 peptide, amycretin, to simplify future manufacturing).

One of the most intriguing hypotheses under investigation in the REDEFINE program is body composition quality. In preclinical rodent DXA studies and early human body-composition analyses, amylin/calcitonin receptor agonism demonstrated a higher ratio of fat mass loss to lean skeletal muscle loss compared with GLP-1 monotherapy. Researchers attribute this to calcitonin/amylin signaling in bone and muscle metabolism as well as improved hypothalamic leptin sensitivity.

On the gastrointestinal side, however, combining full-dose semaglutide (2.4 mg) with cagrilintide (2.4 mg)—both of which slow gastric emptying and stimulate area postrema neurons—produces slightly higher rates of mild-to-moderate nausea and early satiety during escalation than tirzepatide, where GIP receptor activation actively dampens area postrema emetic signaling. That higher satiety intensity explains why more than 40% of REDEFINE-1 participants chose to remain on sub-maximal doses while still losing over 20% of their body weight. Regardless of which agent is studied, preserving skeletal muscle requires structured protein intake and progressive mechanical loading (see our Preventing Muscle Loss on GLP-1s Guide).